Treatment of Cytomegalovirus Colitis — Not Mild Disease
When CMV colitis presents as more than mild disease, the clinical approach differs from milder presentations. This protocol addresses the management of cytomegalovirus colitis in patients whose disease severity exceeds the mild threshold.
Clinical Scenario
Cytomegalovirus colitis that is not mild disease. Oral therapy alone is not appropriate at this severity level; systemic treatment via the IV route is the preferred starting approach.
Treatment Goal
Resolution of signs and symptoms of CMV colitis within the treatment period.
Treatment Approach (partial overview)
IV antiviral therapy is the treatment of choice for non-mild CMV colitis. Once the patient is able to absorb and tolerate oral medications, therapy may be transitioned to an oral antiviral formulation. Treatment continues until signs and symptoms have resolved.
Full regimen details, dosing, and duration are in the structured protocol below.
References
IV ganciclovir is the therapy of choice (AI) and can be switched to oral valganciclovir once the person can tolerate and absorb oral medications, extrapolated from randomized, clinical trial data showing non-inferiority of oral valganciclovir for treatment of CMV disease in people receiving a solid organ transplant (SOT) (AIII).
Oral valganciclovir can be used in patients with mild disease (AIII).
Ganciclovir 5 mg/kg IV every 12 hours (AI); may switch to valganciclovir 900 mg PO every 12 hours once the patient can absorb and tolerate PO therapy (AIII).
21–42 days or until signs and symptoms have resolved (AIII).
View source ↗